1. Introduction

Carotid intima media thickness (cIMT) is a surrogate marker for atherosclerosis.[1] Subclinical arterial wall alterations may be progressive and precede the development of atherosclerosis.

2. Methods

The study was part of a larger cohort study to investigate cardiorespiratory disease in older children with HIV taking ART. Cardiac and lung findings have been published and the full protocol has been described elsewhere.[2,3] Few studies have been conducted in children in Sub-Saharan Africa (SSA), where 90% of the world’s children with HIV live, and findings from high-income settings may differ to SSA children due to variations in access to antiretroviral therapy (ART) as well as racial differences that have been described before.[4] Notably, a significant proportion of children and adolescents with perinatal HIV in SSA have had delayed diagnosis of HIV and/or ART initiation compared with those from high income settings, and this may impact on cardiovascular disease risk. Therefore, the aim of this study was to assess cIMT in children with HIV and receiving ART in an SSA setting.
Blood samples were collected for measurement of HIV-1 viral load and cluster of differentiation 4 (CD4) count testing. Carotid ultrasound was performed using a Mindray DC N6 ultrasound machine (Mindray, Shenzhen, China). Participants were scanned in supine position with a high frequency linear array probe of 12 MHz. With the patient’s head tilted upwards slightly and at 45°, the left and right common carotid arteries were examined respectively. Using two-dimensional images in longitudinal view the carotid bulb was identified and cine loops (10 seconds long) were recorded in Dicom format for later off-line analysis using an automated edge detection system. Intima media thickness measurements were made at approximately 1 to 2 cm from the carotid bulb in triplicate for each side and the average used for analysis.

The study had 80% power to detect a mean difference in cIMT of 0.03 mm and an alpha of 0.05. Unpaired t test was used to compare normally distributed variables and Wilcoxon rank-sum test for variables not normally distributed between the 2 groups. Carotid IMT measures were compared between HIV-infected versus uninfected participants and between HIV-infected participants receiving a protease inhibitor (PI) based regimen compared with a non-PI regimen, using unpaired t tests. The relationship between cIMT and clinical and HIV related factors including CD4 count, viral load, duration of ART, age, body mass index (BMI)-for-age z-score and systolic BP and diastolic BP were analyzed using multiple linear regression using backward stepwise regression.

Ethical approval for this study was obtained from the Medical Research Council of Zimbabwe, the London School of Hygiene and Tropical Medicine Ethics Committee, the Biomedical Research and Training Institute Institutional Review Board, and the Harare Central Hospital Ethics Committee.

### 3. Results

A total of 117 participants with HIV, and 75 HIV uninfected controls underwent cIMT scans. There was no difference by sex between the 2 groups but participants with HIV were younger than controls (mean [SD] age 10.7 [2.4] years vs 11.9 [2.6] years \(P = .001\); shorter (mean height-for-age z-score \(-1.22 [1.0]\) vs \(-0.29 [1.0] [P < .001]\); and had lower median body mass index (BMI) for-age z-score \(-0.47 [−0.09–0.13] vs −0.17 [−0.09–0.63] [P < .019]\) (Table 1). All participants with HIV were perinatally infected with a median age at HIV diagnosis of 5 (interquartile range, 3–7) years. The median duration on ART was 4.8 (interquartile range 2.5–6.4) years and 24 (21%) of participants were receiving PI as part of their ART regimen. All participants on the PI regimen (n = 24) received atazanavir drug boosted with ritonavir. More than 3-quarters of participants with HIV were virally suppressed, 93 (80%).

Carotid IMT did not differ between the 2 groups: mean (SD) 0.40 (0.05) mm in those with HIV and 0.40 (0.04) mm in HIV controls \(P = .377\). There was also no difference in mean cIMT between participants who were and those who were not receiving a PI regimen, 0.40 mm versus 0.40 mm \(P = .809\) and between virally and non-virally suppressed \(P = .514\). Age, systolic BP, BMI-for-age z-score, CD4 count, HIV viral load, and duration on ART were not associated with cIMT. However, diastolic BP was associated with cIMT \(P = .043\).

### 4. Discussion

We found that older children and adolescents with HIV and receiving ART have similar cIMT to uninfected children. This finding is consistent with other reports of children who have had long-term exposure to ART from Indonesia and France.\(^7\)\(^9\)\(^\footnote{ART-experienced children have comparable cIMT to uninfected children could suggest that ART may protect against atherosclerotic changes in childhood. This may be due to slowing of arterial wall structural changes that are associated with HIV infection. A fifth of the participants with HIV were on PI-containing regimen, receiving atazanavir drug, which has been reported to be less atherogenic than other PIs.}\(^\footnote{Data in children from SSA is limited. In one study conducted among Zambian and South African children, the effects of therapy on IMT were not observed.}\)\(^\footnote{Data in children from SSA is limited. In one study conducted among Zambian and South African children, the effects of therapy on IMT were not observed.}\)

### Table 1

Clinical characteristics of the participants.

| Characteristics            | HIV infected N = 117 Mean (SD) | HIV uninfected N = 75 Mean (SD) | P-value |
|---------------------------|--------------------------------|--------------------------------|---------|
| Female, n (%)             | 55 (47)                        | 34 (45)                        | .886    |
| Age, y                    | 10.7 (2.4)                     | 11.9 (2.6)                     | .001    |
| Height-for-age z-score    | \(-1.22 [1.0]\)                | \(-0.29 [1.0]\)                | <.001   |
| Weight-for-age z-score    | \(-1.09 [1.1]\)                | \(-1.09 [1.1]\)                | <.001   |
| BMI-for-age z-score, median (IQR) | \(-0.47 [−0.09–0.13] | \(-1.09 [−0.09–0.63] | .019    |
| Body surface area, m\(^2\) | 1.05 (0.2)                     | 1.05 (0.2)                     | <.001   |
| Systolic BP, mmHg         | 110.6 (11.4)                   | 112.6 (12.9)                   | .267    |
| Diastolic BP, mmHg        | 72.9 (9.0)                     | 73.2 (9.8)                     | .856    |
| Heart rate, beats per minute | 88.1 (14.5)                   | 79.1 (14.2)                   | <.001   |
| Oxygen saturation, %, median (IQR) | 97 (96–98)                   | 98 (96–98)                     | .085    |
| cIMT, mm                  | 0.40 (0.05)                    | 0.40 (0.04)                    | .472    |
| Viral load, copies/mL, median (IQR) | 19 (19–89.5)                 | 19 (19–89.5)                   |         |
| Viral suppression, \(<400 copies/mL\), n (%) | 93 (80)                      | 34 (45)                        |         |
| CD4 count, cells/μL, median (IQR) | 740 (513–880)                | 740 (513–880)                  |         |
| Age at HIV diagnosis, y, median (IQR) | 5 (3–7)                     | 5 (3–7)                        |         |
| Duration on ART, y, median (IQR) | 4.8 (2.5–6.4)                | 4.8 (2.5–6.4)                  |         |
| ART regimen               |                                |                                |         |
| 2NRTI + PI, n (%)         | 24 (21)                        |                                |         |
| 2 NRTI + NNRTI, n (%)     | 88 (75)                        |                                |         |
| Unknown, n (%)            | 5 (4)                          |                                |         |

\(^{ART}\) = antiretroviral therapy, \(^{BMI}\) = body mass index, \(^{BP}\) = blood pressure, \(^{cIMT}\) = carotid intima-media thickness, \(^{IQR}\) = interquartile range, \(^{NNRTI}\) = non-nucleoside reverse transcriptase, \(^{NRTI}\) = nucleoside reverse transcriptase, \(^{PI}\) = protease inhibitor, \(^{SD}\) = standard deviation, \(y\) = years.
Ugandan children with HIV, ART-naive children had significantly higher cIMT, which then improved after 96 weeks of ART initiation. However, the second study conducted among Ethiopian children found that cIMT was similar in the participants regardless of treatment status or ART regimen.

Several studies elsewhere have investigated the association between HIV and cIMT in children and contradicting findings have been reported. Sainz et al.[13] found that Spanish HIV infected children and adolescents, 97% of whom were on ART, had increased cIMT thickness compared with uninfected controls. Other studies have found increased cIMT in adult patients receiving PI based ART regimen compared with non-PI treated or uninfected controls.[13] Inconsistent findings in studies investigating cIMT in HIV may be because of different approaches in assessing cIMT,[2,3,12] the operator-dependency of the technique or due to different underlying drivers of vessel thickening in early life. It is also likely that the contradictory findings in previous studies are due to the operator dependency of ultrasound imaging.

Age and ART were found to be associated with increased cIMT in a study conducted among children in United Kingdom.[15] Vigano et al.[14] reported that HIV infection, longer duration on ART, and male sex were associated with increased cIMT in their cohort aged 17 to 23 from Italy. In this study, diastolic BP was associated with cIMT and no HIV-related factors were associated with cIMT. It is possible that our study was underpowered to detect other associations, or it may be that differences in cIMT at this early age may predominantly represent hypertrophy of intimal and/or medial layers as an adaptive response to blood flow and intraluminal pressure rather than subclinical atherosclerosis.[13]

Causes of subclinical atherosclerosis in HIV are likely multifactorial. Both HIV and traditional cardiovascular risk factors reportedly contribute to atherosclerosis in adults[4] and others speculate that chronic inflammation may be the culprit. Children allow the opportunity to investigate risk factors and mechanisms of subclinical atherosclerosis without confounding by traditional cardiovascular risk factors. There are some limitations to this study. Ultrasound is limited as a technique by its operator dependency. Data on lipid profiles and other cardiovascular biomarkers are lacking and the study was cross-sectional and therefore, no causality can be attributed to the factors that were associated with cIMT.

5. Conclusion

Older children and adolescents with HIV and receiving ART have similar cIMT to children without HIV. Longitudinal investigations of vascular structure and function are required to understand whether children and adolescents in SSA receiving ART are at increased risk of subclinical atherosclerosis.

Acknowledgments

The authors would like to thank Harare Hospital, Paediatric HIV clinic, research staff, participants and their families, and HIV Research Trust. Many thanks to University College London, Institute of Cardiovascular Science (Vascular Physiology Unit), London, United Kingdom for assistance with analysis of the carotid scans.

Author contributions

EDM and RAF designed the study. EDM collected and analysed the data with input from STC. All authors contributed to editing and approved the final version of the manuscript.

Scott T, Chiesa: 0000-0003-4323-2189,
Hilda Mujuru: 0000-0003-1615-3856,
Jon Odland: 0000-0002-2756-0732,
Juan P. Kaski: 0000-0002-0014-9927,
Rashida Ferrand: 0000-0002-7660-9176,
Edith Majonga orcid: 0000-0002-9021-0698.

References

[1] Eckard AR, Raggi P, Ruff JH, et al. Arterial stiffness in HIV-infected youth and associations with HIV-related variables. Virulence 2017; 8:1265–73.
[2] Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005;112:103–9.
[3] Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603–8.
[4] Whincup PH, Nightingale CM, Owen CG, et al. Ethnic differences in carotid intima-media thickness between UK children of black African-Caribbean and white European origin. Stroke 2012;43:1747–54.
[5] Majonga ED, Rehman AM, Simms V, et al. High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. AIDS 2013;27:3739–48.
[6] Rylance J, McHugh G, Metcalfe J, et al. Chronic lung disease in HIV-infected children established on antiretroviral therapy. AIDS 2016; 30:2795–803.
[7] Idris NS, Grobbee DE, Burgner D, et al. Effects of paediatric HIV infection on childhood vasculature. Eur Heart J 2016;37:3610–6.
[8] Bonnete D, Aggouna Y, Szepanski L, et al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS 2004; 18:1037–41.
[9] Cahn PE, Gatell JM, Squires K, et al. Atazanavir–a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians Aids Care (Chic) 2004;3:92–8.
[10] Kenny J, Cook A, Rapala A, et al. Structural Cardiovascular Changes Are Reversible in HIV-Infected Children in Zambia and Uganda. Conference on Retroviruses and Opportunistic Infections. 2015; abstract #37.
[11] Rosebush JC, Gleasson RL, Caufl A, et al. Preclinical Atherosclerosis in Eastern Africa: Results From a Pediatric Ethiopian Cohort. 21st Conference on Retroviruses and Opportunistic Organisms in Boston. 2014;Abstract #917.
[12] Sainz T, Álvarez-Fuente M, Navarro ML, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVH Study. J Acquir Immune Defic Syndr 2014;65:42–9.
[13] Johnsen S, Dolan SE, Fitch KV, et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006;91:916–24.
[14] Vigano A, Bedogni G, Cezini C, et al. Both HIV-infection and long term antiretroviral therapy are associated with increased common carotid intima-media thickness in HIV infected adolescents and young adults. Curr HIV Res 2010;8:411–7.
[15] Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke 1997;28:2442–7.